With little fanfare, Novo Nordisk
Novo Nordisk's inhalable insulin system, dubbed AERx, was in phase 3 testing as a potential short-acting diabetes treatment. Like other inhalable insulins, including Nektar Therapeutics'
In the press release, Novo stated that it was halting development of its inhaled insulin compound because the drug was "unlikely to offer significant clinical or convenience benefits" versus current diabetes treatments. That's also why Pfizer could garner only $12 million in sales of the short-acting Exubera in last year's first nine months, before it handed the product back to Nektar.
Interestingly, Novo didn't say that it was giving up on inhalable insulins, only that it was raising the white flag on its current late-stage AERx program. The company did announce plans to pursue a GLP-1 inhalable diabetes treatment, pitting it against a similar MannKind
Novo also announced plans this week to work on developing a long-acting inhaled insulin product -- a first for any drugmaker, as far as I know. Long-acting insulins sound even less ideal for inhalation than their short-acting counterparts; they're already injected less frequently, giving needle-phobic patients fewer qualms about their use.
Eli Lilly and partner Alkermes
Lilly and Alkermes will probably avoid some of the problems that Exubera faced, such as its confusing dosage quantities and an unwieldy device size, but they probably won't escape all Exubera's woes. This puts MannKind and its completely different Technosphere as the next great rapid-acting inhalable insulin hope. Unless MannKind can prove otherwise, Sanofi-Aventis
More Foolishness on diabetes drug makers:
Eli Lilly is an active Income Investor pick, Pfizer was selected by Inside Value, and MannKind is a Motley Fool Hidden Gems Pay Dirt recommendation. Need new ideas for your money? Give any of our newsletters a try free for 30 days.